Literature DB >> 16769986

Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Brian E Lally1, Daniel Zelterman, Joseph M Colasanto, Bruce G Haffty, Frank C Detterbeck, Lynn D Wilson.   

Abstract

PURPOSE: To investigate the association between survival and postoperative radiotherapy (PORT) in patients with resected non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database, we selected patients with stage II or III NSCLC who underwent a lobectomy or pneumonectomy. Only those patients coded as receiving PORT or observation were included. To account for perioperative mortality, we excluded patients who survived less than 4 months. As a result of our inclusion criteria, we selected a total of 7,465 patients, with a median follow-up time of 3.5 years for patients still alive.
RESULTS: Predictors for the use of PORT included age less than 50 years, higher American Joint Committee on Cancer stage, T3-4 tumor stage, larger tumor size, advanced node stage, greater number of lymph nodes involved, and a ratio of lymph nodes involved to lymph nodes sampled approaching 1.00. On multivariate analysis, older age, T3-4 tumor stage, N2 node stage, male sex, fewer sampled lymph nodes, and greater number of involved lymph nodes had a negative impact on survival. The use of PORT did not have a significant impact on survival. However, in subset analysis for patients with N2 nodal disease (hazard ratio [HR] = 0.855; 95% CI, 0.762 to 0.959; P = .0077), PORT was associated with a significant increase in survival. For patients with N0 (HR = 1.176; 95% CI, 1.005 to 1.376; P = .0435) and N1 (HR = 1.097; 95% CI, 1.015 to 1.186; P = .0196) nodal disease, PORT was associated with a significant decrease in survival.
CONCLUSION: In a population-based cohort, PORT use is associated with an increase in survival in patients with N2 nodal disease but not in patients with N1 and N0 nodal disease.

Entities:  

Mesh:

Year:  2006        PMID: 16769986     DOI: 10.1200/JCO.2005.04.6110

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  113 in total

1.  Is post-operative radiotherapy of any benefit after R0 resection for N2 disease?

Authors:  Robert J Cerfolio; James H Estes
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 2.  Carcinoma of the bronchus 60 years later.

Authors:  G A Silvestri; S G Spiro
Journal:  Thorax       Date:  2006-12       Impact factor: 9.139

3.  Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Authors:  Cliff G Robinson; Aalok P Patel; Jeffrey D Bradley; Todd DeWees; Saiama N Waqar; Daniel Morgensztern; Maria Q Baggstrom; Ramaswamy Govindan; Jennifer M Bell; Tracey J Guthrie; Graham A Colditz; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 4.  Update in lung cancer 2006.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2007-05-01       Impact factor: 21.405

Review 5.  Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?

Authors:  Corey J Langer
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  Sex-specific aspects of tumor therapy.

Authors:  Kerstin Borgmann; Ekkehard Dikomey; Cordula Petersen; Petra Feyer; Ulrike Hoeller
Journal:  Radiat Environ Biophys       Date:  2009-02-26       Impact factor: 1.925

7.  Improving the pathologic evaluation of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Holly L Hilsenbeck; Elizabeth W Sales; Allen Berry; Robert W Jarrett; Christopher S Giampapa; Clara N Finch-Cruz; David Spencer
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 8.  Proton Therapy in Non-small Cell Lung Cancer.

Authors:  Shane Mesko; Daniel Gomez
Journal:  Curr Treat Options Oncol       Date:  2018-11-27

9.  Survival prediction models for estimating the benefit of post-operative radiation therapy for gallbladder cancer and lung cancer.

Authors:  Jayashree Kalpathy-Cramer; William Hersh; Jong Song Kim; Charles R Thomas; Samuel J Wang
Journal:  AMIA Annu Symp Proc       Date:  2008-11-06

Review 10.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.